TheWell Bioscience

At TheWell Bioscience, we believe every person is unique and personalized medicine can improve the quality of life for every patient. We focus on driving advanced biomedicine with our next-generation animal-free hydrogels to drive 3D biomimicking platforms for precision medicine, cell therapy, and biomanufacturing. Closely mimicking the natural extracellular matrix, our defined, synthetic biofunctional 3D cell matrices (VitroGel and VitroINK) enable researchers to shift from 2D to 3D cell culture easier and more consistently than animal-based ECM. Explore an array of high-throughput automation-capable hydrogels and bioinks that can open the door to 3D cell models for preclinical and clinical applications....

3d cell culture,3d bioprinting,hydrogels,bioinks,biomaterials,tissue engineering,regenerative medicine,drug delivery,cell therapy,stem cell scale-up,organoids,msc scale-up,mesenchymal stem cell,personalize medicine,and drug discovery

Thewell bioscience operates in the Biotechnology research industry.

Thewell bioscience's revenue is 11m - 100m

Thewell bioscience has 11 - 50 employees.